OS Therapies (OSTX) Research & Development (2023 - 2026)
OS Therapies' Research & Development was $6.07 million in Q2 2026, up 143.0% from $2.5 million a year earlier but down 17.4% from the prior quarter.
Powered by 
Analysis
OS Therapies (OSTX) Research & Development (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, OS Therapies' Research & Development was $25.98 million through Jun 30, 2026, up 341.1% year-over-year; for FY2025, it came in at $16.36 million, up 476.3% from FY2024.
- In earlier years, Research & Development was $2.84 million in FY2024 (-11.7%) and $3.22 million in FY2023.
- Quarterly Research & Development has moved between $361,809 (Q1 2024) and $8.8 million (Q4 2025) over five years.
- Compared with a year earlier, Research & Development has increased for six straight quarters, with growth averaging 333.7% over the last eight quarters.
- The best year-over-year quarter for Research & Development over five years was Q4 2025 (growth of 910.6%); the worst was Q2 2024 (a decline of 60.1%).
- Per Business Quant data, OSTX's Research & Development in the three quarters before Q2 2026 was $7.35 million (Q1 2026), $8.8 million (Q4 2025) and $3.76 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,130.22 Bn | 1,098.81 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 613.62 Bn | 532.15 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 501.46 Bn | 474.57 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 366.84 Bn | 321.22 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.85 Bn | 261.84 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 235.39 Bn | 190.79 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 169.57 Bn | 116.22 Bn | 10.94 Bn | 2.81 Bn |
| 10 | OS Therapies | 6.21 Mn | 2.94 Mn | - | 6.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.07 Mn |
| Mar 31, 2026 | 7.35 Mn |
| Dec 31, 2025 | 8.80 Mn |
| Sep 30, 2025 | 3.76 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 870,469.00 |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 396,567.00 |
| Mar 31, 2024 | 361,809.00 |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 454,505.00 |
| Jun 30, 2023 | 992,896.00 |
| Mar 31, 2023 | 753,784.00 |
API Access
OS Therapies Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=OSTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "OSTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=OSTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();